DEXA scanning for osteoporosis in patients on aromatase inhbitors – pro
Breast cancer patients are at an increased risk of osteoporosis due to age, cancer, chemotherapy, and aromatase inhibitor therapy. The latter, by depriving the bone of estrogenic stimulation both promotes and accelerates osteoporosis. Because of this, imaging to detect and follow this condition as well as bisphosphonates used to treat osteoporosis, are standard treatment along with the aromatase inhibitor. Guidelines recommend a baseline DEXA
Read more